CN103599084B - 一种降压组合物 - Google Patents

一种降压组合物 Download PDF

Info

Publication number
CN103599084B
CN103599084B CN201310616630.7A CN201310616630A CN103599084B CN 103599084 B CN103599084 B CN 103599084B CN 201310616630 A CN201310616630 A CN 201310616630A CN 103599084 B CN103599084 B CN 103599084B
Authority
CN
China
Prior art keywords
valsartan
lactose
glycerin monostearate
coating agent
tablet composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310616630.7A
Other languages
English (en)
Other versions
CN103599084A (zh
Inventor
张友凯
连艳菊
许蕾
龙连清
Original Assignee
Disha Pharmaceutical Group Co Ltd
Weihai Disu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disha Pharmaceutical Group Co Ltd, Weihai Disu Pharmaceutical Co Ltd filed Critical Disha Pharmaceutical Group Co Ltd
Priority to CN201310616630.7A priority Critical patent/CN103599084B/zh
Publication of CN103599084A publication Critical patent/CN103599084A/zh
Application granted granted Critical
Publication of CN103599084B publication Critical patent/CN103599084B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种缬沙坦片组合物,属于医药技术领域。本发明缬沙坦组合物,每1000片含缬沙坦80g,乳糖62‑69.84g,交联聚维酮10g,单硬脂酸甘油酯0.16‑8g,包衣剂欧巴代3g,其中缬沙坦与乳糖共粉碎至粒径小于75微米。本发明技术方案解决了溶出度低的问题。

Description

一种降压组合物
技术领域:本发明涉及一种缬沙坦片组合物,属于医药技术领域。
背景技术:
缬沙坦是一种血管紧张素(AT)II受体拮抗剂,它选择性的作用于AT1受体。该药1996年首先在德国上市,1998年在我国上市,目前已在世界70多个国家上市。该药具有降压平稳、疗效强、安全性好、副作用低、患者依从性好等诸多优点。
缬沙坦主药流动性很差,国内外生产厂家多数采用干法制粒工艺改善流动性,由于干法制粒对物料润滑性要求较高,故需加入较高比例的硬脂酸镁,这可能导致少量的缬沙坦与镁离子结合形成镁盐,专利CN200510007707.6报道了缬沙坦的镁盐,钙盐,钠盐在理化性质方面与缬沙坦存在不同,这会对其药物制剂的性质和人体的药物作用产生影响。
缬沙坦化合物不溶于水,欧洲专利EP2072049A2中公开了用微晶纤维素作为填充剂的技术方案,由于微晶纤维素不溶于水,不利于难溶性主药的溶出,制备的片剂溶出度偏低。
如何提高缬沙坦片的溶出度,以提高缬沙坦片在体内的溶出,是制剂工作者应该解决的技术问题。
发明内容:
发明目的:本发明要解决的技术问题是缬沙坦片剂的溶出度偏低问题,以提高药物在人体内的释放。
本发明的技术方案是:
本发明采用主药与乳糖共同粉碎后进行制粒的技术,解决了缬沙坦片溶出度低的难题。
一种缬沙坦片剂组合物,其特征在于,每1000片含缬沙坦80g,乳糖62-69.84g,交联聚维酮10g,单硬脂酸甘油酯0.16-8g,包衣剂欧巴代3g,其中缬沙坦与乳糖共粉碎至粒径小于75微米。
本发明优选的技术方案是一种缬沙坦片剂组合物,其特征在于,每1000片含缬沙坦80g,乳糖62g,交联聚维酮10g,单硬脂酸甘油酯8g,包衣剂欧巴代3g。
本发明优选的技术方案是一种缬沙坦片剂组合物,其特征在于,每1000片含缬沙坦80g,乳糖68.4g,交联聚维酮10g,单硬脂酸甘油酯1.6g,包衣剂欧巴代3g。
本发明优选的技术方案是一种缬沙坦片剂组合物,其特征在于,每1000片含缬沙坦80g,乳糖69.84g,交联聚维酮10g,单硬脂酸甘油酯0.16g,包衣剂欧巴代3g。
本发明组合物的制备方法,其特征在于,
第一步:称取处方量的缬沙坦与乳糖,混合均匀。
第二步:粉碎乳糖与缬沙坦的混合物至粒径小于75um。
第三步:将粉碎后的物料加入到流化床制粒机中,进风温度40℃,雾化喷入适量的水,喷液速度5ml/min,制得适宜颗粒。
第四步:将第三步得到的颗粒与处方量的交联聚维酮,单硬脂酸甘油酯加入到三维运动混合机中,混合20min。
第五步:压片,片硬度40-80N。
第六步:包衣,包衣粉均匀分散于纯化水中,包衣液固含量15%,进风温度50℃,片床温度40-45℃,包衣增重2-4%。
有益效果:
本发明技术方案,通过合理配伍和一定的工艺处理,提高了缬沙坦片剂的溶出度。
本发明的另一个有益效果是采用单硬脂酸甘油酯作为润滑剂,代替常规的硬脂酸镁等含有金属离子的润滑剂,且处方中其它辅料均不含金属离子,避免了此类金属离子可能会对缬沙坦的不良影响,在试验过程中我们发现,使用单硬脂酸甘油酯作为润滑剂,在稳定性方面要明显优于含有硬脂酸镁的技术方案。
实施例
按表1的处方和工艺制备对照例1、实施例1、实施例2和实施例3样品。
表1
对照例2
处方:同实施例2。
制备方法:缬沙坦与乳糖混合过80目筛,加入流化床制粒机中,将粘合剂雾化喷入,制得适宜颗粒,与交联聚维酮,单硬脂酸甘油酯混合均匀,压片,包衣
试验例1、
将对照例1、市售缬沙坦片样品、实施例1至3的样品至于60℃的恒温箱中,分别于5天、10天取样检测有关物质,数据记录于表2。
表2、有关物质对比试验结果
表2数据表明:在60℃存放条件下,实施例1-3的样品有关物质含量基本没有变化,而对照例样品随存放时间的延长而升高。说明单硬脂酸甘油酯的配伍为稳定性的提高起到了意想不到的效果。
试验例2、按药典规定的方法,测量对照例2、实施例1至3的样品的溶出度,数据记录于表3.
表3、溶出度对比试验结果
注:溶出度条件:转篮法,转速50rpm,介质pH6.8磷酸缓冲液,37℃,介质体积900ml取样点30min。
表3数据表明:实施例1-3的样品的溶出度高于对照例2,且在60℃存放条件下,实施例1-3样品,溶出度变化很小,而对照例2样品随时间的延长,溶出度逐步降低。
说明本发明技术方案样品的溶出度好于对照例,乳糖与缬沙坦共粉碎起到了意想不到的效果。

Claims (4)

1.一种缬沙坦片剂组合物,其特征在于,每1000 片含缬沙坦80g,乳糖62-69.84g,交联聚维酮10g,单硬脂酸甘油酯0.16-8g,包衣剂欧巴代3g,其中缬沙坦与乳糖共粉碎至粒径小于75 微米,按下述方法制备:
第一步:称取处方量的缬沙坦与乳糖,混合均匀;
第二步:粉碎乳糖与缬沙坦的混合物至粒径小于75 微米;
第三步:将粉碎后的物料加入到流化床制粒机中,进风温度40℃,雾化喷入适量的水,喷液速度5ml/min,制得适宜颗粒;
第四步:将第三步得到的颗粒与处方量的交联聚维酮,单硬脂酸甘油酯混匀;
第五步:压片,片硬度40-80N ;
第六步:包衣,包衣增重2-4%。
2.权利要求1 所述片剂组合物,其特征在于,每1000 片含缬沙坦80g,乳糖62g,交联聚维酮10g,单硬脂酸甘油酯8g,包衣剂欧巴代3g。
3.权利要求1 所述片剂组合物,其特征在于,每1000 片含缬沙坦80g,乳糖68.4g,交联聚维酮10g,单硬脂酸甘油酯1.6g,包衣剂欧巴代3g。
4.权利要求1 所述片剂组合物,其特征在于,每1000 片含缬沙坦80g,乳糖69.84g,交联聚维酮10g,单硬脂酸甘油酯0.16g,包衣剂欧巴代3g。
CN201310616630.7A 2013-11-22 2013-11-22 一种降压组合物 Active CN103599084B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310616630.7A CN103599084B (zh) 2013-11-22 2013-11-22 一种降压组合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310616630.7A CN103599084B (zh) 2013-11-22 2013-11-22 一种降压组合物

Publications (2)

Publication Number Publication Date
CN103599084A CN103599084A (zh) 2014-02-26
CN103599084B true CN103599084B (zh) 2018-10-30

Family

ID=50117393

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310616630.7A Active CN103599084B (zh) 2013-11-22 2013-11-22 一种降压组合物

Country Status (1)

Country Link
CN (1) CN103599084B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103933000B (zh) * 2014-05-06 2021-11-12 山东新时代药业有限公司 一种阿齐沙坦片剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1437469A (zh) * 2000-06-22 2003-08-20 诺瓦提斯公司 药物组合物
CN101087589A (zh) * 2004-12-24 2007-12-12 新梅斯托克尔克公司 含有缬沙坦的固体药物组合物
CN101167723A (zh) * 2006-10-27 2008-04-30 陈益智 缬沙坦分散片及其制备方法
CN102204907A (zh) * 2011-03-31 2011-10-05 北京赛科药业有限责任公司 一种含缬沙坦的药物组合物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120107397A1 (en) * 2009-07-03 2012-05-03 Hetero Research Foundation Pharmaceutical compositions of valsartan

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1437469A (zh) * 2000-06-22 2003-08-20 诺瓦提斯公司 药物组合物
CN101087589A (zh) * 2004-12-24 2007-12-12 新梅斯托克尔克公司 含有缬沙坦的固体药物组合物
CN101167723A (zh) * 2006-10-27 2008-04-30 陈益智 缬沙坦分散片及其制备方法
CN102204907A (zh) * 2011-03-31 2011-10-05 北京赛科药业有限责任公司 一种含缬沙坦的药物组合物及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
单硬脂酸甘油醋的生产及应用;江芸;《杭州化工》;20041231;第34卷(第3期);参见全文 *

Also Published As

Publication number Publication date
CN103599084A (zh) 2014-02-26

Similar Documents

Publication Publication Date Title
TWI439267B (zh) 包含3'-[(2z)-[1-(3,4-二甲基苯基)-1,5-二氫-3-甲基-5-氧代-4h-吡唑-4-亞基]肼基]-2'-羥基-[1,1'-聯苯基]-3-甲酸雙(單乙醇胺)之醫藥錠劑、固態口服醫藥劑型、醫藥膠囊及醫藥顆粒,其用途及用於製備其等之方法
JP6126456B2 (ja) 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠
WO2015097234A1 (en) Pharmaceutical composition of dpp-iv inhibitor in combination with metformin
JP5993965B2 (ja) ソリフェナシンを含む安定した錠剤及びその製造方法
WO2017121340A1 (zh) 阿哌沙班固体组合物及其制备方法
CN104758265B (zh) 一种雷诺嗪缓释片药物组合物及其制备方法
JPWO2009072334A1 (ja) 製剤用核粒子
CN108057021B (zh) 一种孟鲁斯特钠颗粒剂及其制备方法
US20140030346A1 (en) Disintegrable core particle for pharmaceutical preparation
CN103599084B (zh) 一种降压组合物
KR20120127387A (ko) 경구 투여용 의약 조성물
CA2609026A1 (en) Formulations containing losartan and/or its salts
CN106619646B (zh) 一种替吉奥组合物的制备方法
CN102614185A (zh) 缬沙坦和氢氯噻嗪的组合物及其制备方法
ZA200308594B (en) Granular preparations of a gaboxadol.
CN104721827A (zh) 一种难溶性抗真菌药物固体分散体及其制备方法
CN103845332A (zh) 一种达沙替尼药用组合物及其制备方法
JPH02300123A (ja) 消化性潰瘍治療剤
JP6156037B2 (ja) 固形医薬製剤組成物
KR102627892B1 (ko) 항응고제의 신속 방출 약물 제제 및 이의 제조 방법
CN102058602B (zh) 一种稳定的含氯沙坦钾和氢氯噻嗪的口服固体制剂
TW201114422A (en) Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
CN106880597A (zh) 一种依维莫司片
CN104644632A (zh) 含有阿齐沙坦和苯磺酸氨氯地平的口服片剂及其制备方法
EP3052086A1 (en) Pharmaceutical composition comprising low dose active pharmaceutical ingredient and preparation thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C41 Transfer of patent application or patent right or utility model
CB02 Change of applicant information

Address after: 264205, Weihai economic and Technological Zone, Shandong Province, Qingdao South Road, No. 1

Applicant after: DISHA PHARMACEUTICAL GROUP Co.,Ltd.

Applicant after: Shandong Disha Pharmaceutical Co.,Ltd., Disha Phamaceutical Group

Applicant after: WEIHAI DIJIA PHARMACEUTICAL Co.,Ltd.

Address before: 264205, Weihai economic and Technological Zone, Shandong Province, Qingdao South Road, No. 1

Applicant before: DISHA PHARMACEUTICAL GROUP Co.,Ltd.

Applicant before: Shandong Disha Pharmaceutical Co.,Ltd., Disha Phamaceutical Group

Applicant before: WEIHAI DIJIA FINE CHEMICAL Co.,Ltd.

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20160623

Address after: Economic and Technological Development Zone of Shandong Province, Weihai City, Gushan Town, 264000 No. 18 South Road, No. 19 North Road, No. 3 East Road, the west five

Applicant after: WEIHAI DISU PHARMACEUTICAL Co.,Ltd.

Applicant after: DISHA PHARMACEUTICAL GROUP Co.,Ltd.

Address before: 264205, Weihai economic and Technological Zone, Shandong Province, Qingdao South Road, No. 1

Applicant before: DISHA PHARMACEUTICAL GROUP Co.,Ltd.

Applicant before: Shandong Disha Pharmaceutical Co.,Ltd., Disha Phamaceutical Group

Applicant before: WEIHAI DIJIA PHARMACEUTICAL Co.,Ltd.

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20191024

Address after: 264205 Guangzhou East Road South and an East Road East, Wendeng economic and Technological Development Zone, Weihai City, Shandong Province

Co-patentee after: WEIHAI DISU PHARMACEUTICAL Co.,Ltd.

Patentee after: Dijia Pharmaceutical Group Co.,Ltd.

Co-patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd.

Address before: Economic and Technological Development Zone of Shandong Province, Weihai City, Gushan Town, 264000 No. 18 South Road, No. 19 North Road, No. 3 East Road, the west five

Co-patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd.

Patentee before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210906

Address after: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province

Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd.

Address before: 264205 Wendeng economic and Technological Development Zone, Weihai City, Shandong Province

Patentee before: Dijia Pharmaceutical Group Co.,Ltd.

Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd.

Effective date of registration: 20210906

Address after: 264205 Wendeng economic and Technological Development Zone, Weihai City, Shandong Province

Patentee after: Dijia Pharmaceutical Group Co.,Ltd.

Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd.

Address before: 264205 Wendeng economic and Technological Development Zone, Weihai City, Shandong Province

Patentee before: Dijia Pharmaceutical Group Co.,Ltd.

Patentee before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd.

Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd.

TR01 Transfer of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A pressure reducing composition

Effective date of registration: 20220721

Granted publication date: 20181030

Pledgee: Bank of China Limited Weihai Branch

Pledgor: DISHA PHARMACEUTICAL GROUP Co.,Ltd.

Registration number: Y2022980010828

PE01 Entry into force of the registration of the contract for pledge of patent right